Feb 06 2025 35 mins 3
Clinical trials will be launched in the next year or two to test predictions about causal biology made by artificial intelligence models, Vik Bajaj, co-founder and CEO of Foresite Labs and managing director of Foresite Capital Management, believes. Foresite teamed up with Arch Venture Partners last year on a $1 billion venture round to fund Xaira Therapeutics, which aims to reinvent the R&D process via AI-driven protein design and biological discovery technologies.
Bajaj, who serves as interim president of Xaira, discussed the potential for artificial intelligence to accelerate biomedical progress in an interview with Washington Editor Steve Usdin on The BioCentury Show.
View full story: https://www.biocentury.com/article/654977
#biotech #biopharma #pharma #lifescience #AI #RandD #drugdiscovery
00:00 - Introduction
01:18 - AI & Biotech
12:19 - Getting the Data Right
19:06 - Healthcare Delivery
30:47 - Making It Real
